Cryo-Cell (CCEL): Net earnings per share (EPS TTM)

CCEL (cryo-cell.com) - company brandmark

Optimizing cryochamber energy costs as part of its ESG strategy combines with the full localization of business in the US, which eliminates external geopolitical risks. This 12-month net income per share chart visualizes the result of this stability, where -0.24 serves as the current metric level. This price action confirms the effectiveness of Cryo-Cell International (CCEL) leadership in biobanking focused on long-term cell storage for young families.

CCEL cryo-cell.com Earnings per share for the trailing year (07/04/2022 - 11/15/2026)

Analytical breakdowns and data insights for company cryo-cell.com (CCEL)

- current quotes and average value forecast:
Price Chart Cryo-Cell|CCEL - Analyst Median Target
- stock exchange capitalization data:
Market Capitalization CCEL|CCEL - Real Price to Acquire Entire Company
- business book valuation details:
Net Assets per Single Share Cryo-Cell International|CCEL - Accounting Value of Company|Market Cap to Net Assets Ratio cryo-cell.com|CCEL - Company Assets
- debt and liquidity data:
Debt to Equity Cryo-Cell International|CCEL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio cryo-cell.com|CCEL - Company Total Indebtedness|Debts to Book Capitalization CCEL|CCEL - Company Long-Term Liabilities|Company Short-Term Debts Cryo-Cell International|Quick Liquidity cryo-cell.com
- earnings and multiples data:
CCEL - Company Net Income|Expected Profit Cryo-Cell International|CCEL - Price to Earnings Ratio|Projected Price to Earnings Cryo-Cell International, Inc.|CCEL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Cryo-Cell International|CCEL - Operating income before deduction of amortization|Earnings per share for the last twelve months Cryo-Cell International|CCEL - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months cryo-cell.com|CCEL - Net earnings per one share growth for the current year|Earnings growth forecast for next year Cryo-Cell International
- issuer revenue and sales details:
CCEL - Company Total Revenue|Company Projected Revenue Cryo-Cell International, Inc.|CCEL - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Cryo-Cell International|CCEL - Sales Growth YoY (Last 12 Months)
Comprehensive company analysis:Cryo-Cell International Inc (CCEL)
Mass-produced product of Cryo-Cell International

Net income per share over 12 months measures the rolling annual earnings distributed per security. This metric allows for an assessment of real capital generation efficiency by excluding the impact of quarterly fluctuations. Analyzing the rolling earnings per share reveals the true growth vector of the business. For Cryo-Cell International (CCEL), such stability confirms the financial resilience of the oldest biobank in the US. Monolithic client trust converts into predictable asset returns.

Competitor analysis

MESO - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Lineage Cell Therapeutics Inc LCTX|Surrozen Inc. (SRZN) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months FBLG (FibroBiologics Inc.)|Earnings per share for the last twelve months Longeveron Inc|biorestorative.com (BRTX) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) CELZ